Brokers Issue Forecasts for Biogen Inc.’s FY2025 Earnings (NASDAQ:BIIB)

Biogen Inc. (NASDAQ:BIIBFree Report) – Leerink Partnrs lowered their FY2025 earnings per share estimates for Biogen in a research note issued on Monday, January 29th. Leerink Partnrs analyst M. Goodman now expects that the biotechnology company will post earnings per share of $19.50 for the year, down from their prior estimate of $19.65. The consensus estimate for Biogen’s current full-year earnings is $14.95 per share. Leerink Partnrs also issued estimates for Biogen’s FY2026 earnings at $22.10 EPS, FY2027 earnings at $24.40 EPS and FY2028 earnings at $27.05 EPS.

Biogen (NASDAQ:BIIBGet Free Report) last posted its quarterly earnings results on Wednesday, November 8th. The biotechnology company reported $4.36 EPS for the quarter, topping analysts’ consensus estimates of $3.99 by $0.37. The business had revenue of $2.53 billion during the quarter, compared to the consensus estimate of $2.40 billion. Biogen had a return on equity of 16.40% and a net margin of 14.63%. The company’s revenue for the quarter was up .9% compared to the same quarter last year. During the same period last year, the firm earned $4.77 earnings per share.

A number of other brokerages have also recently issued reports on BIIB. Morgan Stanley raised their target price on shares of Biogen from $361.00 to $373.00 and gave the stock an “overweight” rating in a report on Friday, November 10th. William Blair reiterated an “outperform” rating on shares of Biogen in a research report on Wednesday, January 10th. StockNews.com downgraded Biogen from a “buy” rating to a “hold” rating in a research report on Wednesday. Royal Bank of Canada upped their target price on Biogen from $351.00 to $363.00 and gave the stock an “outperform” rating in a research report on Thursday, November 9th. Finally, BTIG Research restated a “neutral” rating on shares of Biogen in a research report on Sunday, January 7th. Seven investment analysts have rated the stock with a hold rating and nineteen have given a buy rating to the company. Based on data from MarketBeat.com, Biogen currently has an average rating of “Moderate Buy” and a consensus target price of $318.17.

Check Out Our Latest Stock Analysis on BIIB

Biogen Stock Performance

Shares of NASDAQ BIIB opened at $246.66 on Tuesday. The company has a quick ratio of 1.09, a current ratio of 1.68 and a debt-to-equity ratio of 0.47. The firm’s 50-day moving average price is $247.99 and its two-hundred day moving average price is $254.13. Biogen has a 52-week low of $220.86 and a 52-week high of $319.76. The stock has a market capitalization of $35.74 billion, a P/E ratio of 24.52, a P/E/G ratio of 2.70 and a beta of 0.05.

Hedge Funds Weigh In On Biogen

Hedge funds have recently modified their holdings of the stock. Bank Julius Baer & Co. Ltd Zurich boosted its holdings in Biogen by 176,592.0% in the second quarter. Bank Julius Baer & Co. Ltd Zurich now owns 2,079,665 shares of the biotechnology company’s stock worth $592,393,000 after purchasing an additional 2,078,488 shares in the last quarter. Norges Bank bought a new stake in Biogen during the fourth quarter valued at about $362,129,000. Price T Rowe Associates Inc. MD boosted its holdings in Biogen by 49.5% during the first quarter. Price T Rowe Associates Inc. MD now owns 2,088,356 shares of the biotechnology company’s stock valued at $580,627,000 after acquiring an additional 691,843 shares during the period. International Assets Investment Management LLC boosted its holdings in Biogen by 24,726.3% during the fourth quarter. International Assets Investment Management LLC now owns 476,913 shares of the biotechnology company’s stock valued at $123,411,000 after acquiring an additional 474,992 shares during the period. Finally, abrdn plc boosted its holdings in Biogen by 237.4% during the fourth quarter. abrdn plc now owns 437,075 shares of the biotechnology company’s stock valued at $113,102,000 after acquiring an additional 307,532 shares during the period. 85.99% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Biogen

In other news, insider Priya Singhal sold 110 shares of the company’s stock in a transaction on Monday, December 11th. The shares were sold at an average price of $248.00, for a total value of $27,280.00. Following the transaction, the insider now directly owns 3,464 shares of the company’s stock, valued at $859,072. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 0.60% of the stock is currently owned by company insiders.

About Biogen

(Get Free Report)

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.

Featured Stories

Earnings History and Estimates for Biogen (NASDAQ:BIIB)

Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.